Low-dose chemotherapy as a prelude to intensive treatment of spontaneous leukemia-lymphoma in AKR mice. J Natl Cancer Inst 1975 Jul;55(1):219-21
Date
07/01/1975Pubmed ID
1159816DOI
10.1093/jnci/55.1.219Scopus ID
2-s2.0-0016751512 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Groups of AKR mice bearing spontaneous leukemia-lymphoma were treated with five different combinations of chemotherapy or chemoradiotherapy. Each treatment combination was given in two sequences--high dose first and low dose last, or low dose first and high dose last--administered over 6-7 days. When the initial treatment was a high dose of chemotherapy, radiotherapy, or chemoradiotherapy, mortality in the first 24 hours exceeded 40%, and at least 70% of the mice in each group were dead within 2 weeks. When low-dose chemotherapy was given first, mortality in the first 24 hours was minimal but, most significantly, no deaths occurred in the 24 hours after subsequent high-dose treatment. In the most successful group (100 mg cyclophosphamide/kg on day 0, and 250 mg cyclophosphamide/kg and 400 R total-body X-irradiation on day 7), the median survival time increased significantly as compared with the median survival time among mice given the same regimen in reverse sequence (p less than 0.001) or among untreated control mice (p less than 0.01). With this regimen, survival 60 days after the last treatment was 47%. No mouse survived 30 days when the sequence of treatments was reversed. From these results, we conclude that chemotherapeutic and chemoradiotherapeutic regimens for AKR spontaneous leukemia-lymphoma should be designed so that low, minimally lethal doses precede higher doses.
Author List
Rose WC, Rimm AA, Saltzstein EC, Truitt RL, Bortin MMMESH terms used to index this publication - Major topics in bold
Amphotericin BAnimals
Cyclophosphamide
Dose-Response Relationship, Drug
Dose-Response Relationship, Radiation
Female
Leukemia
Lymphoma
Mice
Mice, Inbred AKR
Nitrosourea Compounds
